Get the Stockscreener App
44.12
1.29%
0.56
After Hours:
44.12
Livanova Plc stock is traded at $44.12, with a volume of 465.90K.
It is up +1.29% in the last 24 hours and down -3.18% over the past month.
UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
See More
Previous Close:
$43.56
Open:
$43.655
24h Volume:
465.90K
Relative Volume:
0.67
Market Cap:
$2.41B
Revenue:
$1.28B
Net Income/Loss:
$-222.15M
P/E Ratio:
-10.79
EPS:
-4.09
Net Cash Flow:
$145.52M
1W Performance:
+2.63%
1M Performance:
-3.18%
6M Performance:
-9.63%
1Y Performance:
-19.18%
1-Day Range:
$43.55
$44.20
1-Week Range:
$41.94
$44.20
52-Week Range:
$32.48
$57.35
Livanova Plc Stock (LIVN) Company Profile
Name
Livanova Plc
Sector
Industry
Phone
4402033250662
Address
20 EASTBOURNE TERRACE, LONDON
Compare LIVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LIVN
Livanova Plc
|
44.12 | 2.38B | 1.28B | -222.15M | 145.52M | -4.09 |
|
ABT
Abbott Laboratories
|
125.83 | 218.75B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
107.76 | 152.62B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
400.93 | 151.01B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
92.01 | 117.43B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.91 | 44.76B | 5.54B | 4.18B | 623.10M | 7.00 |
Livanova Plc Stock (LIVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Feb-26-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Oct-04-24 | Initiated | Goldman | Buy |
| Sep-17-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-20-24 | Reiterated | Needham | Buy |
| Feb-20-24 | Upgrade | Mizuho | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Hold |
| Jul-19-23 | Initiated | Robert W. Baird | Neutral |
| Apr-14-23 | Initiated | Mizuho | Neutral |
| Dec-21-22 | Initiated | Barclays | Equal Weight |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Feb-24-22 | Upgrade | UBS | Neutral → Buy |
| Dec-03-21 | Initiated | Goldman | Buy |
| Aug-20-21 | Reiterated | Needham | Buy |
| Jul-20-21 | Upgrade | Needham | Hold → Buy |
| Mar-03-21 | Downgrade | Berenberg | Buy → Hold |
| Jan-05-21 | Downgrade | Needham | Buy → Hold |
| Sep-02-20 | Initiated | Robert W. Baird | Outperform |
| Jun-26-20 | Reiterated | Needham | Buy |
| Oct-30-19 | Reiterated | Needham | Buy |
| Feb-28-19 | Reiterated | Needham | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Aug-02-18 | Reiterated | Needham | Buy |
| Jun-08-18 | Initiated | Stifel | Buy |
| May-31-18 | Reiterated | Needham | Buy |
| Feb-28-18 | Reiterated | Needham | Buy |
View All
Livanova Plc Stock (LIVN) Latest News
Is LivaNova PLC a good long term investmentHigh-impact stock picks - jammulinksnews.com
External Pacemakers Market Set to Witness Significant Growth - openPR.com
What drives LivaNova PLC stock priceBreakthrough financial growth - Autocar Professional
LivaNova PLC Stock Analysis and ForecastAccelerated wealth expansion - Autocar Professional
What analysts say about LivaNova PLC stockDynamic growth stocks - jammulinksnews.com
Cardiac Autonomic Control Market Growth in Future Scope - openPR.com
In-Line Blood Monitoring Devices Market is projected to grow - openPR.com
Wearable Cardioverter Defibrillators Market is projected - openPR.com
Jefferies Reiterates a Buy Rating on LivaNova PLC (LIVN) With a $79 PT - MSN
Neuro Modulation Devices Market is expected to reach US$ 7.6 - openPR.com
(LIVN) Technical Data - news.stocktradersdaily.com
‘A vicious life loop’: Epilepsy community calls for action to address the burden of disease - medianet.com.au
Principal Financial Group Inc. Purchases 3,668 Shares of LivaNova PLC (NASDAQ:LIVN) - Defense World
10 Undervalued Medical Device Stocks to Buy Now - Insider Monkey
How LivaNova PLC stock performs during market volatilityStable Stocks With High Yield - Newser
Why LivaNova PLC stock attracts strong analyst attentionInsider Strategy Insight - Newser
Vagus Nerve Stimulators Market Exclusive Report with Detailed - openPR.com
LivaNova to Announce Second-Quarter 2025 Results | LIVN Stock Ne - GuruFocus
LivaNova to Announce Second-Quarter 2025 Results - Business Wire
LivaNova: The Sell-Off Is Excessive Here (NASDAQ:LIVN) - Seeking Alpha
Here's Why LivaNova (NASDAQ:LIVN) Can Manage Its Debt Responsibly - 富途牛牛
LivaNova PLC (LIVN): A High-Conviction Buy at Oversold Levels - AInvest
Trading (LIVN) With Integrated Risk Controls - news.stocktradersdaily.com
LivaNova PLC(NasdaqGS: LIVN) dropped from Russell 2000 Growth Index - MarketScreener
LivaNova PLC(NasdaqGS: LIVN) dropped from Russell 2000 Growth-Defensive Index - MarketScreener
Are Options Traders Betting on a Big Move in LivaNova Stock? - Nasdaq
Latest Developments and Regulatory Approvals - openPR.com
LivaNova Announces CORE-VNS 24-Month Data - Medical Product Outsourcing
Global Neuromodulation Market to grow at a CAGR of 8.95% by 2030, - openPR.com
Global Neuromodulation Market to grow at a CAGR of 8.95% by 2030, Evaluates DelveInsight | Medtronic, Abbott, Boston Scientific Corp, LivaNova, NeuroSigma, Inc., NEVRO CORP., Synapse Biomedical Inc - Barchart.com
Global Neurostimulation Devices Market to grow at a CAGR - openPR.com
(LIVN) Investment Report - news.stocktradersdaily.com
LivaNova’s SWOT analysis: medical device firm’s stock faces growth hurdles By Investing.com - Investing.com Nigeria
Livanova Plc Stock (LIVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):